Yahoo
NYSE - Nasdaq Real Time Price USD

Zimmer Biomet Holdings, Inc. (ZBH)

106.85 -3.30 (-3.00%)
At close: November 5 at 4:00:03 PM EST
106.85 0.00 (0.00%)
After hours: November 5 at 6:03:02 PM EST
Trade ZBH on Coinbase
ZBH Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for ZBH

What's happening with ZBH?

9m ago
Powered by Yahoo Scout

Zimmer Biomet reported a mixed but generally positive third quarter, with revenue and adjusted EPS slightly above estimates. Management raised 2026 guidance, supported by hip, S.E.T., and technology growth, while knee weakness and margin pressure remain central risks. ZBH was down 3.00% in today’s pre-market move against the prior close, before the regular session opened.

Powered by Yahoo Scout
  • Previous Close 110.15
  • Open 111.00
  • Bid --
  • Ask --
  • Day's Range 105.50 - 111.15
  • 52 Week Range 79.12 - 112.55
  • Volume 3,623,453
  • Avg. Volume 2,089,362
  • Market Cap (intraday) 20.38B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 26.98
  • EPS (TTM) 3.96
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 0.96 (0.87%)
  • 1y Target Est 106.90
  • Morningstar Rating Rating available with Stock Picks access

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

www.zimmerbiomet.com

17,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZBH
19.78%
S&P 500 (^GSPC)
7.42%

1-Year Return

ZBH
23.35%
S&P 500 (^GSPC)
8.20%

3-Year Return

ZBH
1.08%
S&P 500 (^GSPC)
68.73%

5-Year Return

ZBH
18.79%
S&P 500 (^GSPC)
56.54%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 2.06B
Earnings 191.6M
Profit Margin 9.29%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
2B
2B
7.0%
8.0%
9.0%
10.0%
11.0%

Analyst Insights

View More

Analyst Price Targets

93.00 Low
106.90 Average
106.85 Current
130.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/6/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 120 -> 130

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.48%

  • Return on Assets (ttm)

    3.88%

  • Return on Equity (ttm)

    6.41%

  • Revenue (ttm)

    8.51B

  • Net Income Avi to Common (ttm)

    806.7M

  • Diluted EPS (ttm)

    3.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    464.5M

  • Total Debt/Equity (mrq)

    60.18%

  • Levered Free Cash Flow (ttm)

    1.07B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: